Repurposing niclosamide for COVID-19: Synergistic strategies of nanotechnology and novel materials to enhance antiviral efficacy
Microbial Pathogenesis · 2026
DOI: 10.1016/j.micpath.2025.108169 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Microbial Pathogenesis, 2026. Verfasst von Haichuan Rong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Cell Biology, Department of Cell Biology, Ministry of Public Health and Key Laboratory of Medical Cell Biology, Ministry of Educati…. Hauptthemen laut MEDLINE: Niclosamide, COVID-19 Drug Treatment, Drug Repositioning, Antiviral Agents. Die Arbeit nennt 111 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The persistent prevalence of COVID-19 and its emerging variants continues to threaten global health security. While most of these viruses have been controlled through medications or vaccines, the increasing number of SARS-CoV-2 variants and the inequitable access to vaccines across nations remain significant challenges for epidemiological management. Niclosamide, an FDA-approved anthelmintic drug, exhibits broad-spectrum antitumor, antibacterial, and antiviral properties, yet suffers from poor bioavailability. Repurposing niclosamide in combination with advanced material technologies may offer a promising therapeutic strategy. To optimize its future clinical applications, we summarize the antiviral mechanisms of niclosamide and emphasize strategies such as nanotechnology and novel material design to enhance its bioavailability and stability. Additionally, we discuss the latest clinical trial outcomes of niclosamide. Looking ahead, with the ongoing advancements in material synthesis, the synergistic integration of nano-hybridization and innovative material systems for niclosamide is poised to become a pivotal tool in epidemiological management and combating viral threats, providing an innovative, accessible, and cost-effective solution for pandemic control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Cell Biology, Department of Cell Biology, Ministry of Public Health and Key Laboratory of Medical Cell Biology, Ministry of Education, School of Life Sciences, China Medical University, Shenyang, Liaon…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Rong, H., Ren, J., Wu, Q., Zhu, H., Dong, C., & Wang, G. (2026). Repurposing niclosamide for COVID-19: Synergistic strategies of nanotechnology and novel materials to enhance antiviral efficacy. Microbial Pathogenesis. https://doi.org/10.1016/j.micpath.2025.108169
Vancouver
Rong H, Ren J, Wu Q, Zhu H, Dong C, Wang G. Repurposing niclosamide for COVID-19: Synergistic strategies of nanotechnology and novel materials to enhance antiviral efficacy. Microbial Pathogenesis. 2026. doi:10.1016/j.micpath.2025.108169
BibTeX
@article{Rong2026,
author = {Rong, Haichuan and Ren, Junyi and Wu, Qifeng and Zhu, Haijun and Dong, Chenshuang and Wang, Guiling},
title = {Repurposing niclosamide for COVID-19: Synergistic strategies of nanotechnology and novel materials to enhance antiviral efficacy},
journal = {Microbial Pathogenesis},
year = {2026},
doi = {10.1016/j.micpath.2025.108169}
}
EUVIMED